Skip to main content
Erschienen in: Pathology & Oncology Research 3/2008

01.09.2008 | Original Paper

Expression of p21waf1/cip1, p27kip1, p63 and Androgen Receptor in Low and High Gleason Score Prostate Cancer

verfasst von: Imre Romics, Gergely Bánfi, Eszter Székely, Tibor Krenács, Béla Szende

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the expression of p21waf1/cip1, p27kip1, p63 and androgen receptor proteins in relation to serum prostate specific antigen levels in low and high Gleason score prostate cancers. Biopsies of patients suffering from prostate adenocarcinoma of low (3 + 3 to 3 + 4) and high (5 + 4 to 5 + 5) Gleason scores (13 cases each group) were immunostained for positive regulators of cell cycle control (p21waf1/cip1 and p27kip1), and essential markers of normal prostate gland ontogeny (p63) and growth (androgen receptor) to find differentially expressed markers of malignant progression. Serum prostate specific antigen levels were also monitored at the time of biopsy and following anti-androgen therapy. All cases except one in each group were androgen receptor positive. P63 and p21waf1/cip1 proteins detected in normal basal cell nuclei were lost in all but one studied tumors respectively. P27kip1 protein, however, was detected in all low Gleason score prostate cancers, but it was found in only 7/13 high score cases. Prostate specific antigen levels, either pre- or post-treatment, did not show strict correlation with the p27kip1 results. The low to high grade dedifferentiation of prostate adenocarcinoma is accompanied with the down-regulation of p27kip1 protein, which may be an important molecular sign of the lost cell cycle control.
Literatur
1.
Zurück zum Zitat Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF (1992) Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 13:457–464PubMed Isaacs JT, Lundmo PI, Berges R, Martikainen P, Kyprianou N, English HF (1992) Androgen regulation of programmed death of normal and malignant prostatic cells. J Androl 13:457–464PubMed
2.
Zurück zum Zitat Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G, Klocker H (2001) Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol 40:241–251CrossRefPubMed Eder IE, Culig Z, Putz T, Nessler-Menardi C, Bartsch G, Klocker H (2001) Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol 40:241–251CrossRefPubMed
3.
Zurück zum Zitat Stamey TA, Warrington JA, Caldwell MC et al (2001) Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 166:2171–2177CrossRefPubMed Stamey TA, Warrington JA, Caldwell MC et al (2001) Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 166:2171–2177CrossRefPubMed
4.
Zurück zum Zitat Porkka KP, Visakorpi T (2001) Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library assay. J Pathol 193:73–79CrossRefPubMed Porkka KP, Visakorpi T (2001) Detection of differentially expressed genes in prostate cancer by combining suppression subtractive hybridization and cDNA library assay. J Pathol 193:73–79CrossRefPubMed
5.
Zurück zum Zitat Meehan KL, Holland JW, Dawkins HJ (2002) Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50:54–63CrossRefPubMed Meehan KL, Holland JW, Dawkins HJ (2002) Proteomic analysis of normal and malignant prostate tissue to identify novel proteins lost in cancer. Prostate 50:54–63CrossRefPubMed
6.
Zurück zum Zitat Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U (1999) Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80:546–555CrossRefPubMed Baretton GB, Klenk U, Diebold J, Schmeller N, Lohrs U (1999) Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80:546–555CrossRefPubMed
7.
Zurück zum Zitat Eder IE, Bektic J, Haag P, Bartsch G, Klocker H (2004) Genes differentially expressed in prostate cancer. BJU Int 93:1151–1155CrossRefPubMed Eder IE, Bektic J, Haag P, Bartsch G, Klocker H (2004) Genes differentially expressed in prostate cancer. BJU Int 93:1151–1155CrossRefPubMed
8.
Zurück zum Zitat Szende B, Romics I, Minik K, Szabó J, Torda I, Lovász S, Tóth L, Bély M, Kerényi T, Bartók K, Végh A (2001) Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma. Prostate 49:93–100CrossRefPubMed Szende B, Romics I, Minik K, Szabó J, Torda I, Lovász S, Tóth L, Bély M, Kerényi T, Bartók K, Végh A (2001) Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma. Prostate 49:93–100CrossRefPubMed
9.
Zurück zum Zitat Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattecharya N, Cirenei N, Loda M (2001) Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 15:765–782CrossRefPubMed Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattecharya N, Cirenei N, Loda M (2001) Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol 15:765–782CrossRefPubMed
10.
Zurück zum Zitat Koffer L, Roshong S, Park IK, Cesen-Cummings K, Thopson DR, Dwyer-Nield LD, Rice P, Mamay C, Malkinson AM, Ruch RJ (2000) Growth inhibition in G1 and altered expression of cyclin D1 and p27kip1 after forced connexin expression in lung and liver carcinoma cells. J Cell Biochem 79:347–354CrossRef Koffer L, Roshong S, Park IK, Cesen-Cummings K, Thopson DR, Dwyer-Nield LD, Rice P, Mamay C, Malkinson AM, Ruch RJ (2000) Growth inhibition in G1 and altered expression of cyclin D1 and p27kip1 after forced connexin expression in lung and liver carcinoma cells. J Cell Biochem 79:347–354CrossRef
11.
Zurück zum Zitat Zhang Y-W, Morite I, Ikeda M, Ma K-W, Murota S (2001) Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27. Oncogene 20:4138–4149CrossRefPubMed Zhang Y-W, Morite I, Ikeda M, Ma K-W, Murota S (2001) Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27. Oncogene 20:4138–4149CrossRefPubMed
12.
Zurück zum Zitat Gorbe A, Becker DL, Dux L, Stelkovics E, Krenacs L, Bagdi E, Krenacs T (2005) Transient upregulation of connenxin43 gap junctions and synchronized cell cycle control precede myoblast fusion in regenerating skeletal muscle in vivo. Histochem Cell Biol 123:573–583CrossRefPubMed Gorbe A, Becker DL, Dux L, Stelkovics E, Krenacs L, Bagdi E, Krenacs T (2005) Transient upregulation of connenxin43 gap junctions and synchronized cell cycle control precede myoblast fusion in regenerating skeletal muscle in vivo. Histochem Cell Biol 123:573–583CrossRefPubMed
13.
Zurück zum Zitat Lawlor MA, Rotwein P (2000) Coordinate control of muscle cell survival by distinct insulin-like growth factor activated signaling pathways. J Cell Biol 151:1131–1140CrossRefPubMed Lawlor MA, Rotwein P (2000) Coordinate control of muscle cell survival by distinct insulin-like growth factor activated signaling pathways. J Cell Biol 151:1131–1140CrossRefPubMed
14.
Zurück zum Zitat Ostrovsky O, Bengal E (2003) The mitogen-activated protein kinase cascade promotes myoblast cell survival by stabilizing the cyclin-dependent kinase inhibitor, p21WAF1 protein. J Biol Chem 278:21221–21231CrossRefPubMed Ostrovsky O, Bengal E (2003) The mitogen-activated protein kinase cascade promotes myoblast cell survival by stabilizing the cyclin-dependent kinase inhibitor, p21WAF1 protein. J Biol Chem 278:21221–21231CrossRefPubMed
15.
Zurück zum Zitat Fizazi K, Martizez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM (2002) The association of p21 (WAF-1/CIP1) with progression to androgen-independent prostate cancer. Clin Cancer Res 8:775–781PubMed Fizazi K, Martizez LA, Sikes CR, Johnston DA, Stephens LC, McDonnell TJ, Logothetis CJ, Trapman J, Pisters LL, Ordonez NG, Troncoso P, Navone NM (2002) The association of p21 (WAF-1/CIP1) with progression to androgen-independent prostate cancer. Clin Cancer Res 8:775–781PubMed
16.
Zurück zum Zitat Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M (2000) P63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775PubMed Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M (2000) P63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775PubMed
17.
Zurück zum Zitat Ronison IB (2003) Tumor cell senescence in cancer treatment. Cancer Res 63:2705–2715 Ronison IB (2003) Tumor cell senescence in cancer treatment. Cancer Res 63:2705–2715
18.
Zurück zum Zitat Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C (2002) P63 expression profiles in human normal and tumor tissues. Clin Can Res 8:494–501 Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C (2002) P63 expression profiles in human normal and tumor tissues. Clin Can Res 8:494–501
19.
Zurück zum Zitat Cordon-Cardo G, Koff A, Drobnjak M, Caodieci P, Osman I, Millard SS (1998) Distinct altered patterns of 27kip1 gene expression in benign prostate hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90:1284–1291CrossRefPubMed Cordon-Cardo G, Koff A, Drobnjak M, Caodieci P, Osman I, Millard SS (1998) Distinct altered patterns of 27kip1 gene expression in benign prostate hyperplasia and prostatic carcinoma. J Natl Cancer Inst 90:1284–1291CrossRefPubMed
20.
Zurück zum Zitat Guo Y, Sklar GN, Borkowski A, Kyprianou N (1997) Loss of the cyclin dependent kinase inhibitor p27(Kip1) protein in human prostate cancers correlates with tumor grade. Clin Cancer Res 3:2269–2274PubMed Guo Y, Sklar GN, Borkowski A, Kyprianou N (1997) Loss of the cyclin dependent kinase inhibitor p27(Kip1) protein in human prostate cancers correlates with tumor grade. Clin Cancer Res 3:2269–2274PubMed
21.
Zurück zum Zitat Kuczyk M, Machtens S, Hradil K et al (1999) Predictive value of p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 81:1052–1058CrossRefPubMed Kuczyk M, Machtens S, Hradil K et al (1999) Predictive value of p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients. Br J Cancer 81:1052–1058CrossRefPubMed
22.
Zurück zum Zitat Doganavsargil B, Simsir A, Boyacioglu H, Cal C, Hekimgil M (2006) A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma. BJU Int 97:644–648CrossRefPubMed Doganavsargil B, Simsir A, Boyacioglu H, Cal C, Hekimgil M (2006) A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma. BJU Int 97:644–648CrossRefPubMed
Metadaten
Titel
Expression of p21waf1/cip1, p27kip1, p63 and Androgen Receptor in Low and High Gleason Score Prostate Cancer
verfasst von
Imre Romics
Gergely Bánfi
Eszter Székely
Tibor Krenács
Béla Szende
Publikationsdatum
01.09.2008
Verlag
Springer Netherlands
Erschienen in
Pathology & Oncology Research / Ausgabe 3/2008
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-008-9042-z

Weitere Artikel der Ausgabe 3/2008

Pathology & Oncology Research 3/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.